Please login to the form below

What pharma needs to know about genomic data in 2016

Consultant David Cooney from Blue Latitude Health talks us through what this progress in genomics means for pharma in 2016.
Since the Genome Project started in 1990, genetics has been the “great hope” of healthcare, promising to solve the great mystery of how illness and disease affect us on an individual level. About ten years ago, personalised medicine was a major step forward – tailoring treatments based on individual patient history and information. Fast forward to 2016, and investigating the central dogma of biology is still a major focus of healthcare research.

Now, more researchers are adopting a systems biology approach, combining genetic data with phenotypic data, such as patient records and clinical information, along with metabolomoics and epigenomics. At the forefront of this trend are Human Longevity Inc. and Calico, who are leveraging this multi-discipline approach to target the single biggest risk factor in all human disease – ageing.

Consultant David Cooney talks us through what this progress in genomics means for pharma in 2016.


Partnerships between major players will be increasingly important

Partnerships between companies like the Human Longevity Inc. (HLI), Calico, 23andme, and the award-winning Color Genomics mean that we’ll start to see some innovative research and development work in this area. While this may seem like future-gazing, the reality is that pharma companies are already collaborating with these companies.

Work by HLI in partnership with Calico is incredibly important because it’s pushing this research into the clinic to impact patient care. We believe 2016 will be the year we start to see the fruits of these partnerships emerge from R&D into the commercial space with innovative, genetic-based services. Which means that pharma needs to consider whether their value proposition will still hold if the competition is able to support their brands with genomic data.


Download the full article from Blue Latitude Health here


3rd February 2016

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health
Crusader House
145-157 St John Street
London
EC1V 4QJ
United Kingdom

Latest content on this profile

The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today.
Blue Latitude Health
Medical information in precision medicine
Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine.
Blue Latitude Health
Behavioural insights to navigate complex healthcare markets
Blue Latitude Health Head of Insight Martine Leroy reveals how her team uses behavioural insights to help develop strong pharma brands and services, which successfully navigate complex situations.
Blue Latitude Health
Biotech: it's a people business
Nancy Hunter is the Marketing Director at a cutting-edge pharmaceutical company. Here she explains how a sharp focus on patients’ needs is driving a new operating model for marketing first-in-class drugs, and she describes how her mother’s experience as a cancer patient has shaped her own outlook on healthcare.
Blue Latitude Health
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges and opportunities while introducing the latest issue of 'Perspective' magazine on this weighty topic.
Blue Latitude Health
Personas: a top tool for personalising pharma marketing campaigns
Healthcare customers are calling for greater personalisation in care from providers. Here, we explain why personas are the top tool for ensuring your brand meets this need efficiently and effectively.
Blue Latitude Health